The deal size was increased to $1.5B in common stock from $750M in common stock. JPMorgan, TD Cowen and Guggenheim acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $200 from $140 at Evercore ISI
- Revolution Medicines price target raised to $175 from $160 at Guggenheim
- Revolution Medicines price target raised to $162 from $140 at RBC Capital
- Revolution Medicines price target raised to $169 from $73 at H.C. Wainwright
- Revolution Medicines files to sell $750M of common stock